Positive News SentimentPositive NewsNASDAQ:ONCT Oncternal Therapeutics (ONCT) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free ONCT Stock Alerts $9.00 +0.80 (+9.76%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$8.00▼$9.2550-Day Range$6.90▼$10.1552-Week Range$5.22▼$16.60Volume14,511 shsAverage Volume13,546 shsMarket Capitalization$24.21 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Oncternal Therapeutics alerts: Email Address Oncternal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside255.6% Upside$32.00 Price TargetShort InterestHealthy0.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$6,455 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($12.03) to ($11.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.39 out of 5 starsMedical Sector341st out of 938 stocksPharmaceutical Preparations Industry149th out of 417 stocks 3.2 Analyst's Opinion Consensus RatingOncternal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Oncternal Therapeutics has a forecasted upside of 255.6% from its current price of $9.00.Amount of Analyst CoverageOncternal Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.56% of the float of Oncternal Therapeutics has been sold short.Short Interest Ratio / Days to CoverOncternal Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncternal Therapeutics has recently decreased by 6.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncternal Therapeutics does not currently pay a dividend.Dividend GrowthOncternal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCT. Previous Next 3.3 News and Social Media Coverage News SentimentOncternal Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oncternal Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for ONCT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Oncternal Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncternal Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,455.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of Oncternal Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.05% of the stock of Oncternal Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Oncternal Therapeutics are expected to grow in the coming year, from ($12.03) to ($11.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncternal Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncternal Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncternal Therapeutics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Oncternal Therapeutics Stock (NASDAQ:ONCT)Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.Read More ONCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCT Stock News HeadlinesMarch 15, 2024 | globenewswire.comOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerMarch 13, 2024 | markets.businessinsider.comNorthland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 10, 2024 | finance.yahoo.comOncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 8, 2024 | finance.yahoo.comQ4 2023 Oncternal Therapeutics Inc Earnings CallMarch 8, 2024 | msn.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | benzinga.comOncternal Therapeutics's Earnings: A PreviewMarch 7, 2024 | msn.comONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023March 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 7, 2024 | benzinga.comRecap: Oncternal Therapeutics Q4 EarningsMarch 7, 2024 | washingtonpost.comOncternal Therapeutics: Q4 Earnings SnapshotMarch 7, 2024 | globenewswire.comOncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | markets.businessinsider.comOncternal Therapeutics earnings: here's what to expectFebruary 29, 2024 | globenewswire.comOncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial ResultsFebruary 25, 2024 | finance.yahoo.comOncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash WiselyFebruary 6, 2024 | finance.yahoo.comOncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 3, 2024 | morningstar.comOncternal Therapeutics Inc ONCTJanuary 30, 2024 | ca.finance.yahoo.comONCT Jul 2024 7.500 callJanuary 30, 2024 | ca.finance.yahoo.comONCT Apr 2024 2.500 callJanuary 8, 2024 | finance.yahoo.comOncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerJanuary 4, 2024 | msn.comOncternal Therapeutics announces a reverse stock splitJanuary 4, 2024 | finance.yahoo.comOncternal Therapeutics Announces Reverse Stock SplitDecember 26, 2023 | nasdaq.comOncternal Therapeutics Updates Early Disease Response Data For ONCT-808; Shares FallDecember 26, 2023 | msn.comOncternal Therapeutics Reports Patient Death In Mid-Stage Blood Cancer Study Treated With Second Dose LevelDecember 26, 2023 | finance.yahoo.comOncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell LymphomaDecember 21, 2023 | benzinga.comOncternal Therapeutics Stock (NASDAQ:ONCT) Dividends: History, Yield and DatesDecember 4, 2023 | realmoney.thestreet.comOncternal Therapeutics upgraded to Buy from Hold at BrooklineSee More Headlines Receive ONCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCT CUSIPN/A CIK1260990 Webwww.oncternal.com Phone(858) 434-1113Fax901-844-8075Employees27Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$40.00 Low Stock Price Target$26.00 Potential Upside/Downside+255.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($13.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,480,000.00 Net Margins-5,029.17% Pretax Margin-5,029.17% Return on Equity-95.87% Return on Assets-83.56% Debt Debt-to-Equity RatioN/A Current Ratio6.94 Quick Ratio6.94 Sales & Book Value Annual Sales$790,000.00 Price / Sales30.65 Cash FlowN/A Price / Cash FlowN/A Book Value$10.19 per share Price / Book0.88Miscellaneous Outstanding Shares2,690,000Free Float2,474,000Market Cap$24.21 million OptionableOptionable Beta1.27 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. James B. Breitmeyer M.D. (Age 70)Ph.D., President, CEO & Director Comp: $814.67kDr. Salim Yazji M.D. (Age 55)Chief Medical Officer Comp: $549.21kMr. Richard G. Vincent CPA (Age 60)CFO & Treasurer Comp: $524.48kDr. Rajesh Krishnan Ph.D. (Age 50)Chief Technical & Scientific Officer Mr. Chase C. Leavitt (Age 42)General Counsel & Secretary Mr. Pablo UrbanejaSenior Vice President of Corporate DevelopmentAnita WisethSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsAprea TherapeuticsNASDAQ:APREKALA BIONASDAQ:KALABullfrog AINASDAQ:BFRGBioVieNASDAQ:BIVIIterum TherapeuticsNASDAQ:ITRMView All CompetitorsInsiders & InstitutionsDavid F HaleBought 714 shares on 2/23/2024Total: $6,454.56 ($9.04/share)Citadel Advisors LLCBought 54,279 shares on 2/15/2024Ownership: 1.841%Pasadena Private Wealth LLCBought 221,250 shares on 1/11/2024Ownership: 16.961%Gunnar F KaufmannBought 150 shares on 6/14/2023Total: $1,080.00 ($7.20/share)Gunnar F KaufmannBought 1,250 shares on 6/12/2023Total: $8,750.00 ($7.00/share)View All Insider TransactionsView All Institutional Transactions ONCT Stock Analysis - Frequently Asked Questions Should I buy or sell Oncternal Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCT, but not buy additional shares or sell existing shares. View ONCT analyst ratings or view top-rated stocks. What is Oncternal Therapeutics' stock price target for 2024? 6 brokers have issued 1 year target prices for Oncternal Therapeutics' shares. Their ONCT share price targets range from $26.00 to $40.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 255.6% from the stock's current price. View analysts price targets for ONCT or view top-rated stocks among Wall Street analysts. How have ONCT shares performed in 2024? Oncternal Therapeutics' stock was trading at $10.7240 at the beginning of 2024. Since then, ONCT shares have decreased by 16.1% and is now trading at $9.00. View the best growth stocks for 2024 here. When is Oncternal Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ONCT earnings forecast. How were Oncternal Therapeutics' earnings last quarter? Oncternal Therapeutics, Inc. (NASDAQ:ONCT) posted its earnings results on Thursday, March, 7th. The company reported ($3.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.09) by $0.02. The business had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.17 million. Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative trailing twelve-month return on equity of 95.87%. During the same quarter in the previous year, the firm earned ($4.00) earnings per share. When did Oncternal Therapeutics' stock split? Oncternal Therapeutics's stock reverse split on the morning of Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Oncternal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX). Who are Oncternal Therapeutics' major shareholders? Oncternal Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Pasadena Private Wealth LLC (16.96%), Citadel Advisors LLC (1.84%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Chase C Leavitt, Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent and Salim Yazji. View institutional ownership trends. How do I buy shares of Oncternal Therapeutics? Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONCT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy SykesThe 3rd Revolution in WarfareWeiss RatingsFed launches fourth dollar overhaulStansberry ResearchAI to Meet the Same Fate as EVs? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.